Camrelizumab Shows Promise in Boosting Survival for High-Risk Nasopharyngeal Carcinoma

A recent phase 3 clinical trial has demonstrated that adding the immunotherapy drug camrelizumab to standard chemoradiotherapy significantly improves progression-free survival in patients with high-risk nasopharyngeal carcinoma. The findings, published in The BMJ, offer a potential new avenue for treatment, particularly for those with factors suggesting a higher risk of recurrence.

Understanding Nasopharyngeal Carcinoma and Current Treatment

Nasopharyngeal carcinoma (NPC) is a cancer that affects the nasopharynx, the upper part of the throat behind the nose. Standard treatment for loco-regionally advanced NPC typically involves induction chemotherapy with gemcitabine and cisplatin, followed by concurrent chemoradiotherapy . While this approach improves outcomes, recurrence remains a concern, especially in patients with stage T4, N3 disease or persistent circulating Epstein-Barr virus (EBV) DNA after initial treatment.

The GEM20110714 Phase 3 Trial: Camrelizumab’s Impact

The GEM20110714 trial, conducted across seven hospital centers in China between August 2020 and June 2022, enrolled 390 patients aged 18 to 70 with high-risk, non-keratinizing nasopharyngeal carcinoma. Participants were randomly assigned to receive either standard chemoradiotherapy plus camrelizumab (administered every three weeks for 19 cycles) or standard treatment alone .

Key Findings

• Progression-Free Survival: After a median follow-up of 39.9 months, progression-free survival at 36 months was 83.4% in the camrelizumab group, compared to 71.3% in the standard treatment group. This represents a relative risk reduction of approximately 49% .
• Overall Survival: While overall survival at 36 months reached 94.8% in the camrelizumab group versus 92.2% in the control group, the difference was not statistically significant at this point in follow-up (p = 0.19). Further follow-up is needed to assess the long-term impact on overall survival.
• Distant Metastasis-Free Survival: The rate of survival without distant metastasis at 36 months was 88.9% in the camrelizumab group, compared to 80.7% in the standard group (p = 0.02).
• Locoregional Relapse-Free Survival: Survival without loco-regional relapse at 36 months was 92.8% with camrelizumab, compared to 83.2% with standard treatment (p = 0.001).
• Safety: Grade 3 or 4 acute adverse reactions occurred in 50.5% of patients receiving camrelizumab, compared to 48.7% in the standard group, indicating comparable toxicity. Severe immunological adverse events were reported in 10.2% of patients receiving camrelizumab.

What Does This Mean for Patients?

The addition of camrelizumab to standard treatment appears to significantly improve control of the disease, both locally and in terms of preventing distant spread, without substantially increasing severe toxicity. The observed improvement in progression-free survival, locoregional control, and metastatic control suggests that anti-PD1 immunotherapy could become an vital part of the therapeutic strategy for high-risk nasopharyngeal carcinoma, particularly in patients with an incomplete response or persistent EBV DNA after induction chemotherapy.

Future Directions

Prolonged follow-up of the GEM20110714 trial participants is crucial to confirm the effect on overall survival and to further evaluate the long-term benefit-risk profile of adding camrelizumab to treatment regimens. This research paves the way for potential changes in clinical practice and offers hope for improved outcomes for individuals facing this challenging cancer.